Louise E Craig, Sandy Middleton, Helen Hamilton, Fern Cudlip, Victoria Swatzell, Andrei V Alexandrov, Elizabeth Lightbody, Dame Caroline Watkins, Sheeba Philip, Dominique A Cadilhac, Elizabeth McInnes, Simeon Dale, Anne W Alexandrov
Background: Strict criteria for recombinant tissue plasminogen activator (rtPA) eligibility are stipulated on licences for use in ischaemic stroke; however, practitioners may also add non-standard rtPA criteria. We examined eligibility criteria variation in 3 English-speaking countries including use of non-standard criteria, in relation to rtPA treatment rates. Methods: Surveys were mailed to 566 eligible hospitals in Australia (AUS), the UK, and the USA. Criteria were pre-classified as standard (approved indication and contraindications) or non-standard (approved warning or researcher "decoy")...
February 2020: Interventional Neurology